MX2020005830A - Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos. - Google Patents

Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos.

Info

Publication number
MX2020005830A
MX2020005830A MX2020005830A MX2020005830A MX2020005830A MX 2020005830 A MX2020005830 A MX 2020005830A MX 2020005830 A MX2020005830 A MX 2020005830A MX 2020005830 A MX2020005830 A MX 2020005830A MX 2020005830 A MX2020005830 A MX 2020005830A
Authority
MX
Mexico
Prior art keywords
human
human animals
light chain
antibodies
animals
Prior art date
Application number
MX2020005830A
Other languages
English (en)
Inventor
John Mcwhirter
Andrew J Murphy
Chunguang Guo
Lynn Macdonald
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2020005830A publication Critical patent/MX2020005830A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1264—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan animales no humanos (y/o células no humanas) y métodos para usarlos, dichos animales no humanos (y/o células no humanas) tienen un genoma que comprende secuencias que codifican anticuerpos humanos (es decir, genes de inmunoglobulina). Los animales no humanos descritos en la presente expresan anticuerpos que contienen cadenas ligeras de inmunoglobulina (Ig) caracterizadas por la presencia de dominios V? humanos. Los animales no humanos proporcionados en la presente se caracterizan, en algunas modalidades, por la expresión de anticuerpos que contienen cadenas ligeras de V? humanas que son codificadas por secuencias codificantes de cadenas ligeras de Ig? humanas insertadas en un locus de cadena ligera de Ig? endógena de dichos animales no humanos. También se proporcionan métodos para producir anticuerpos a partir de animales no humanos, cuyos anticuerpos contienen regiones variables humanas y regiones constantes de ratón.
MX2020005830A 2017-12-05 2018-12-04 Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos. MX2020005830A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762594946P 2017-12-05 2017-12-05
US201762594944P 2017-12-05 2017-12-05
US201762609251P 2017-12-21 2017-12-21
US201762609241P 2017-12-21 2017-12-21
PCT/US2018/063841 WO2019113065A1 (en) 2017-12-05 2018-12-04 Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof

Publications (1)

Publication Number Publication Date
MX2020005830A true MX2020005830A (es) 2020-08-20

Family

ID=64734263

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020005830A MX2020005830A (es) 2017-12-05 2018-12-04 Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos.
MX2024004496A MX2024004496A (es) 2017-12-05 2020-07-13 Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024004496A MX2024004496A (es) 2017-12-05 2020-07-13 Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos.

Country Status (24)

Country Link
US (4) US20210345591A1 (es)
EP (3) EP4140297B1 (es)
JP (3) JP7430636B2 (es)
KR (2) KR102760506B1 (es)
CN (2) CN111432635B (es)
AU (2) AU2018381316B2 (es)
BR (1) BR112020011184A2 (es)
CA (1) CA3084049A1 (es)
DK (2) DK4140297T3 (es)
ES (2) ES3035461T3 (es)
FI (1) FI4140297T3 (es)
HR (2) HRP20221459T1 (es)
HU (2) HUE060608T2 (es)
IL (2) IL318197A (es)
LT (2) LT3720279T (es)
MX (2) MX2020005830A (es)
PL (2) PL4140297T3 (es)
PT (2) PT3720279T (es)
RS (2) RS63772B1 (es)
SG (1) SG11202003044SA (es)
SI (2) SI4140297T1 (es)
SM (2) SMT202200448T1 (es)
TW (2) TW202438676A (es)
WO (1) WO2019113065A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
EP3699190B9 (en) 2013-02-22 2023-10-04 Regeneron Pharmaceuticals, Inc. Murine cell expressing humanized major histocompatibility complex
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
HUE060608T2 (hu) 2017-12-05 2023-03-28 Regeneron Pharma Genetikailag módosított immunglobulin lambda könnyûlánccal rendelkezõ egerek és azok alkalmazása
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
BR112021016173A2 (pt) 2019-02-22 2021-11-03 Regeneron Pharma Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma
DK3993623T3 (da) * 2019-07-01 2025-05-26 Zoetis Services Llc Transgene gnavere og fremgangsmåder til anvendelse deraf
CN114502725B (zh) * 2019-07-01 2025-09-12 特里安尼公司 转基因哺乳动物及使用方法
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
CN116848254B (zh) 2020-12-16 2026-03-17 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
IL303865A (en) 2020-12-23 2023-08-01 Regeneron Pharma Methods for obtaining antibodies that bind transmembrane proteins and cells that produce them
CN114763558B (zh) * 2021-01-14 2024-02-20 上海泰槿生物技术有限公司 重组基因组、非人哺乳动物细胞及其产生方法和用途
CN118511853A (zh) * 2021-03-31 2024-08-20 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
CN121065267A (zh) * 2024-06-04 2025-12-05 赛业（苏州）生物科技有限公司 用于制备四元固定轻链的基因修饰的啮齿动物及其制备方法
EP4671705A1 (de) 2024-06-25 2025-12-31 Harro Höfliger Verpackungsmaschinen GmbH Vorrichtung und verfahren zum prüfen des sprühstrahls einer baugruppe für sprühapplikatoren
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
CA2722378C (en) * 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP2319301B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
AU2008297070A1 (en) * 2007-09-12 2009-03-19 Probiodrug Ag Transgenic mice
EP2147594B1 (en) * 2008-06-27 2013-11-13 Merus B.V. Antibody producing non-human mammals
AU2009298458B2 (en) 2008-09-30 2015-10-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
DK3622815T3 (da) 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
US9445581B2 (en) * 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
PT3034608T (pt) 2010-06-22 2019-05-28 Regeneron Pharma Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana
ME02106B (me) 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
SG11201401181YA (en) 2011-10-17 2014-04-28 Regeneron Pharma Restricted immunoglobulin heavy chain mice
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG10201605675WA (en) * 2011-12-20 2016-09-29 Regeneron Pharma Humanized light chain mice
EP3597038B1 (en) * 2012-02-01 2021-04-21 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
ME03551B (me) * 2012-06-12 2020-07-20 Regeneron Pharma Humanizovane nehumane živoтinje sa ograničenim lokusima imunoglobulinskog тeškog lanca
MX384291B (es) 2013-02-20 2025-03-14 Regeneron Pharma Modificación genética de ratas.
DK3456831T3 (da) 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
AU2014330922A1 (en) 2013-10-01 2016-03-03 Kymab Limited Animal models and therapeutic molecules
ES2781323T3 (es) 2014-06-23 2020-09-01 Regeneron Pharma Montaje de ADN mediado por nucleasas
KR102531016B1 (ko) 2014-11-21 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물
ES2947714T3 (es) 2014-12-19 2023-08-17 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida a través de múltiples direccionamientos en un solo paso
KR102483193B1 (ko) 2016-06-03 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
HUE060608T2 (hu) 2017-12-05 2023-03-28 Regeneron Pharma Genetikailag módosított immunglobulin lambda könnyûlánccal rendelkezõ egerek és azok alkalmazása

Also Published As

Publication number Publication date
IL274797B2 (en) 2025-06-01
TW202438676A (zh) 2024-10-01
MX2024004496A (es) 2024-05-08
IL274797B1 (en) 2025-02-01
SMT202200448T1 (it) 2023-01-13
DK4140297T3 (da) 2025-06-23
JP2021505141A (ja) 2021-02-18
JP7765514B2 (ja) 2025-11-06
PT4140297T (pt) 2025-07-09
EP4596688A2 (en) 2025-08-06
EP4596688A3 (en) 2025-11-12
HUE060608T2 (hu) 2023-03-28
WO2019113065A1 (en) 2019-06-13
CN111432635A (zh) 2020-07-17
US20210345591A1 (en) 2021-11-11
LT4140297T (lt) 2025-07-25
EP4140297A1 (en) 2023-03-01
IL274797A (en) 2020-07-30
AU2018381316B2 (en) 2025-06-26
CA3084049A1 (en) 2019-06-13
ES3035461T3 (en) 2025-09-03
AU2018381316A1 (en) 2020-04-23
SMT202500277T1 (it) 2025-09-12
ES2928995T3 (es) 2022-11-24
RS63772B1 (sr) 2022-12-30
SI4140297T1 (sl) 2025-08-29
FI4140297T3 (fi) 2025-07-10
US20190223418A1 (en) 2019-07-25
US11051498B2 (en) 2021-07-06
LT3720279T (lt) 2022-10-25
PL4140297T3 (pl) 2025-08-25
RU2020118699A (ru) 2022-01-10
KR20250022220A (ko) 2025-02-14
BR112020011184A2 (pt) 2020-11-17
JP2024036440A (ja) 2024-03-15
HUE071852T2 (hu) 2025-09-28
TW201938019A (zh) 2019-10-01
RS67058B1 (sr) 2025-08-29
AU2025204547A1 (en) 2025-07-10
HRP20221459T1 (hr) 2023-01-20
EP3720279B1 (en) 2022-09-21
US20210292439A1 (en) 2021-09-23
TWI827567B (zh) 2024-01-01
KR20200093570A (ko) 2020-08-05
IL318197A (en) 2025-03-01
RU2020118699A3 (es) 2022-04-07
CN111432635B (zh) 2022-10-21
KR102760506B1 (ko) 2025-02-04
US20260020545A1 (en) 2026-01-22
SI3720279T1 (sl) 2022-11-30
EP4140297B1 (en) 2025-05-21
DK3720279T3 (da) 2022-10-24
JP2026016575A (ja) 2026-02-03
CN116058333A (zh) 2023-05-05
HRP20250920T1 (hr) 2025-09-26
JP7430636B2 (ja) 2024-02-13
EP3720279A1 (en) 2020-10-14
PT3720279T (pt) 2022-10-06
US12356967B2 (en) 2025-07-15
PL3720279T3 (pl) 2023-01-16
SG11202003044SA (en) 2020-04-29

Similar Documents

Publication Publication Date Title
MX2020005830A (es) Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos.
MX2021010556A (es) Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente.
CY1122036T1 (el) Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα
NZ629639A (en) Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
MX379533B (es) Ratones de cadena ligera universal humanizados.
NZ793447A (en) Humanized rodents that express heavy chains containing vl domains
MX2023001726A (es) Anticuerpos anti-c5 y usos de los mismos.
CY1121798T1 (el) Αντισωματα ελαφριων αλυσιδων τροποποιημενων με ιστιδινη και γενετικα τροποποιημενα ζωα πλην του ανθρωπου για τη δημιουργια αυτων
CY1123046T1 (el) Ζωα εκτος του ανθρωπου που εχουν ανθρωποποιημενους υποδοχεις fc-γ
MY185881A (en) Non-human animals with modified immunoglobulin heavy chain sequences
IN2014DN08163A (es)
MX2016009050A (es) Construcciones biespecificas de union a los antigenos cd3 y cd19.
MX2021014818A (es) Anticuerpos monoclonales anti-cd303.
WO2010076400A8 (fr) Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome intraoculaire primitif
MX2024009271A (es) Constructos de anticuerpos de acidos nucleicos optimizados.
EP4257599A3 (en) Rodents having an engineered heavy chain diversity region
EP4249502A3 (en) Rodents expressing humanized c1q complex